Biocept, Inc. announced that its Target Selector™ assays are now available to physicians in order to evaluate the cerebrospinal fluid of their patients for the presence of circulating tumor cells and biomarkers for patients with breast or lung cancer suspected of brain or central nervous system metastases. The presence of tumor cells in CSF may be an indicator of brain metastases, which occurs when cancer has spread into the CNS. Up to 30% and 36% of patients diagnosed with breast and lung cancer, respectively, will develop brain metastases.